

**NOVOGEN LIMITED**

(ASX: NRT)



## **ASX RELEASE**

22 October 2014

### **NOVOGEN ANNOUNCES APPOINTMENT OF TLM FOR ITS ASX BOOKBUILD AND WEBINAR**

**22 OCT 2014. SYDNEY:** Novogen is pleased to announce the appointment of CMC Markets Australia as the Technical Lead Manager (TLM) for its capital-raising through the ASX Bookbuild facility.

The Company also announces that a webinar will be held on October 29 to provide investors with the opportunity to learn more about the Company, its plans for the future, and the details of the capital-raising.

#### **TLM Appointment**

Andy Rogers, Head of Stockbroking at CMC Markets said today, “the ASX BookBuild facility helps to bring transparency to the capital-raising process, and we’re delighted to establish our presence in this space to help companies of all sizes raise capital in an open and efficient manner.”

Novogen is a bio-pharmaceutical business with enormous potential and its future is what attracted us to launch our efforts here and now as the role of Technical Lead Manager,” added Rogers.

Rosemary Kennedy, of On-Market BookBuilds said, “the ASX Bookbuild facility allows all sophisticated investors, both existing holders, and prospective, to participate in the capital raising. Any investors can bid in via their broker (under the ticker code **NRTXBB**), creating a broad investor base for the company. If an investor’s broker has not provided the investor with the ASX BookBuild agreement, then CMC markets has a quick and easy process for opening an account. That investor will then have access to all future capital raisings that use the ASX BookBuild facility”.

The minimum investment is \$5,000.

Brokers will receive a stamping fee of 5% for successful allocations.

Dr Graham Kelly, Novogen CEO, said, “As we have made clear in a previous announcement, we are raising funds largely to bring our lead drug candidate, Cantrixil, into the clinic to treat patients with end-stage cancers of the abdomen. This is an entirely new approach to a very large problem, and in combination with our joint venture partner, Yale University, we are on track to bring Cantrixil into two Phase 1 studies in mid-2015.”

Alongside the presentations through Sydney and Melbourne, Novogen will be hosting a live webinar on the 29<sup>th</sup> October, 2014 to allow for existing investors and those considering the company for the first time to become acquainted with the management and the cancer-fighting project at hand.

### **Webinar**

Date: 29<sup>th</sup> October, 2014

Time: 12pm AEDT (NSW, VIC, TAS, ACT)

Schedule: 20 min presentation and 30 min Q&A

Registration Details: <https://www.media-server.com/m/go/Novogen-20141029>

OR Scan the QR code below to view on iPad/iPhone/Android Smart Devices.



Company CEO, Dr Graham Kelly, will open the webinar by speaking to the Investor Roadshow Presentation, and then will conduct a Q&A session involving Company senior executives.

### **About CMC Markets Stockbroking**

The CMC Markets Group, a leading independent financial services provider, offers a range of investment products and investment tools including Contracts for Difference (CFDs), shares, options, listed managed investments, warrants, interest rate securities. In 2007 CMC Markets launched its broking service, CMC Markets Stockbroking, which is now one of the few remaining non-bank aligned, online stockbrokers in Australia. CMC Markets Stockbroking [www.cmcmarkets.com.au](http://www.cmcmarkets.com.au) is a participant of the ASX Group and is regulated by ASIC in Australia.

The CMC Markets Blog provides the latest news and analysis from our market analysts and strategists <http://blog.cmcmarkets.com.au>

### **About Novogen Limited**

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven, Connecticut-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website [www.novogen.com](http://www.novogen.com)

For more information please contact:

**Novogen Enquiries**

Dr Graham Kelly

CEO Novogen Group

[Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)

+(61 2) 9472 4100

**Media Enquiries**

Ian Westbrook

Westbrook Communications

[ian@westbrookfin.com.au](mailto:ian@westbrookfin.com.au)

+(61 2) 9231 0922

**Advisor to the Offer**

Matt Christensen

Hill Capital

[matthewc@hillcapital.com.au](mailto:matthewc@hillcapital.com.au)

+(61 2) 9416 5399

**Media Enquiries**

Jacqueline Dearle

CMC Markets Stockbroking

[j.dearle@cmcmarkets.com](mailto:j.dearle@cmcmarkets.com)

+(61 2) 9221 2124

@CMCMarketsANZ